Drugs that contain Meloxicam

1. Drug name - ANJESO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512727 BAUDAX Nanoparticulate meloxicam formulations
Dec, 2022

(15 days from now)

US10463673 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(1 year, 2 months from now)

US10471067 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(1 year, 2 months from now)

US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(7 years from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(7 years from now)

US10709713 BAUDAX Nanoparticulate meloxicam formulations
May, 2030

(7 years from now)

US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment
Mar, 2039

(16 years from now)

US11458145 BAUDAX Methods of administering intravenous meloxicam in a bolus dose
Mar, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30MG/ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

2. Drug name - QMIIZ ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879 TERSERA Fast disintegrating compositions of meloxicam
Aug, 2030

(7 years from now)

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
7.5MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
15MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued

3. Drug name - VIVLODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526734 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2033

(10 years from now)

US9808468 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2035

(12 years from now)

US9649318 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2035

(12 years from now)

Market Authorisation Date: 22 October, 2015

Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam; Management of osteoarthritis pain by administering 5 mg of meloxicam

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG CAPSULE;ORAL Discontinued
10MG CAPSULE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.